Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $6
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $8 to $6.
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $8 to $6.